GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » NonCurrent Deferred Liabilities

Incyte (WBO:INCY) NonCurrent Deferred Liabilities

: €0 Mil (As of Dec. 2023)
View and export this data going back to 2017. Start your Free Trial

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Incyte's non-current deferred liabilities for the quarter that ended in Dec. 2023 was €0 Mil.

Incyte NonCurrent Deferred Liabilities Historical Data

The historical data trend for Incyte's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Incyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
NonCurrent Deferred Liabilities Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Incyte NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Incyte's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (WBO:INCY) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » NonCurrent Deferred Liabilities
Comparable Companies
KRTX SRPT RPRX TECH UTHR LEGN BMRN VKTX ASND ROIV OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Website
https://www.incyte.com
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.